Shots:
- The companies signed an agreement to manufacture movantik for opioid-induced constipation and RHB-204, currently in a P-III US study as a stand-alone 1L treatment for pulmonary NTM disease
- Movantik is the leading prescribed oral peripherally acting mu-opioid receptor antagonist (PAMORA) in the US specifically designed to treat OIC in adult patients with chronic non-cancer pain
- RHB-204 has received FDA Fast Track, OD, and QIDP designations aimed at accelerating development and FDA review and extending the US market exclusivity to a potential total of 12 yrs. (to be granted at the time of FDA approval)
Click here to read full press release/ article | Ref: RedHill | Image: RedHill
The post RedHill Signs a Manufacturing Agreement with Cosmo for Movantik and RHB-204 first appeared on PharmaShots.
